Lupin Limited has informed the Exchange that Board of Directors at its meeting held on May 14, 2025, recommended Final Dividend of 12 per equity share i.e. 600 % of the Face Value of Rs. 2/ Each Fully Paid Up for the Financial Year Ended March 31, 2025

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹2082.00

prior close

₹2100.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.7%-1.3% vs market

Pharmaceuticals peers, median of 150sector+0.4%-1.0% vs sector

On the reaction day the stock moved 1.3 pts less than Nifty Midcap 150 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-0.7

15m

-0.9

30m

-1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6+0.7-1.3+0.4-1.0

Next day

-0.8+1.6-2.4+0.9-1.7

-2.6+1.7-4.3+2.0-4.5

-5.4+0.1-5.5+1.2-6.6

-4.4+0.9-5.3+1.9-6.3

-5.5+0.6-6.0+2.0-7.5

-4.5+1.7-6.2+1.7-6.2

15d

-4.2+4.1-8.2+2.8-6.9

-3.3+4.6-7.9+2.9-6.2

-6.0+6.5-12.5+4.8-10.9

-5.3+3.0-8.3+0.2-5.4

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin reported strong consolidated FY25 results with revenue from operations rising to ₹22,708 crore from ₹20,011 crore in FY24, a growth of about 13.5%. Consolidated profit after tax jumped nearly 71% to ₹3,306 crore from ₹1,936 crore in FY24, with basic EPS of ₹71.95 (vs ₹42.05). Standalone PAT also grew about 71% to ₹3,973 crore on revenue of ₹16,968 crore. The Board recommended a final dividend of ₹12 per share (600% on face value of ₹2), totaling ₹547.9 crore, subject to shareholder approval. Key one-off items include a ₹856 crore provision for ongoing disputes, Glumetza litigation settlement of ~₹75 crore, and impairment charges of ~₹121 crore (consolidated). The company also approved transfer of its OTC and API R&D businesses to wholly owned subsidiaries.

Likely market impact

Strong double-digit revenue growth and ~71% PAT growth, combined with a healthy 600% dividend, signal robust operational performance and shareholder returns. The one-off provisions and impairments temper the underlying picture but core profitability remains materially improved.